Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Addiction Medicine
Buprenorphine for treatment of opiate dependence reviewed
September 5th, 2004
A researcher reviews buprenorphine for the treatment of opiate dependence in a recent issue of the Journal of Psychoactive Drugs. According to a study from the United States, "Buprenorphine's physiological effects are produced when it attaches to specific opiate receptors that are designated mu, kappa, or delta. Buprenorphine, a partial agonist at the mu receptor and an antagonist at the kappa receptor, produces typical morphine-like effects at low doses. At higher doses, it produces opiate effects that are less than those of full opiate agonists." "Knowledge of the physiological effects of opiate receptors and the way they interact with...
Source: Medical Letter on the CDC & FDA (2004-09-05)
|
